Cargando…

The association of hepatic steatosis and fibrosis with heart failure and mortality

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is a hepatic manifestation of metabolic disease and independently affects the development of cardiovascular (CV) disease. We investigated whether hepatic steatosis and/or fibrosis are associated with the development of incident heart failure (iHF)...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Jiyun, Kim, Gyuri, Kim, Hasung, Lee, Jungkuk, Lee, You-Bin, Jin, Sang-Man, Hur, Kyu Yeon, Kim, Jae Hyeon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479901/
https://www.ncbi.nlm.nih.gov/pubmed/34583706
http://dx.doi.org/10.1186/s12933-021-01374-8
_version_ 1784576358325682176
author Park, Jiyun
Kim, Gyuri
Kim, Hasung
Lee, Jungkuk
Lee, You-Bin
Jin, Sang-Man
Hur, Kyu Yeon
Kim, Jae Hyeon
author_facet Park, Jiyun
Kim, Gyuri
Kim, Hasung
Lee, Jungkuk
Lee, You-Bin
Jin, Sang-Man
Hur, Kyu Yeon
Kim, Jae Hyeon
author_sort Park, Jiyun
collection PubMed
description BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is a hepatic manifestation of metabolic disease and independently affects the development of cardiovascular (CV) disease. We investigated whether hepatic steatosis and/or fibrosis are associated with the development of incident heart failure (iHF), hospitalized HF (hHF), mortality, and CV death in both the general population and HF patients. METHODS: We analyzed 778,739 individuals without HF and 7445 patients with pre-existing HF aged 40 to 80 years who underwent a national health check-up from January 2009 to December 2012. The presence of hepatic steatosis and advanced hepatic fibrosis was determined using cutoff values for fatty liver index (FLI) and BARD score. We evaluated the association of FLI or BARD score with the development of iHF, hHF, mortality and CV death using multivariable-adjusted Cox regression models. RESULTS: A total of 28,524 (3.7%) individuals in the general population and 1422 (19.1%) pre-existing HF patients developed iHF and hHF respectively. In the multivariable-adjusted model, participants with an FLI ≥ 60 were at increased risk for iHF (hazard ratio [HR], 95% confidence interval [CI], 1.30, 1.24–1.36), hHF (HR 1.54, 95% CI 1.44–1.66), all-cause mortality (HR 1.62, 95% CI 1.54–1.70), and CV mortality (HR 1.41 95% CI 1.22–1.63) in the general population and hHF (HR 1.26, 95% CI 1.21–1.54) and all-cause mortality (HR 1.54 95% CI 1.24–1.92) in the HF patient group compared with an FLI < 20. Among participants with NAFLD, advanced liver fibrosis was associated with increased risk for iHF, hHF, and all-cause mortality in the general population and all-cause mortality and CV mortality in the HF patient group (all p < 0.05). CONCLUSION: Hepatic steatosis and/or advanced fibrosis as assessed by FLI and BARD score was significantly associated with the risk of HF and mortality. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12933-021-01374-8.
format Online
Article
Text
id pubmed-8479901
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-84799012021-09-29 The association of hepatic steatosis and fibrosis with heart failure and mortality Park, Jiyun Kim, Gyuri Kim, Hasung Lee, Jungkuk Lee, You-Bin Jin, Sang-Man Hur, Kyu Yeon Kim, Jae Hyeon Cardiovasc Diabetol Original Investigation BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is a hepatic manifestation of metabolic disease and independently affects the development of cardiovascular (CV) disease. We investigated whether hepatic steatosis and/or fibrosis are associated with the development of incident heart failure (iHF), hospitalized HF (hHF), mortality, and CV death in both the general population and HF patients. METHODS: We analyzed 778,739 individuals without HF and 7445 patients with pre-existing HF aged 40 to 80 years who underwent a national health check-up from January 2009 to December 2012. The presence of hepatic steatosis and advanced hepatic fibrosis was determined using cutoff values for fatty liver index (FLI) and BARD score. We evaluated the association of FLI or BARD score with the development of iHF, hHF, mortality and CV death using multivariable-adjusted Cox regression models. RESULTS: A total of 28,524 (3.7%) individuals in the general population and 1422 (19.1%) pre-existing HF patients developed iHF and hHF respectively. In the multivariable-adjusted model, participants with an FLI ≥ 60 were at increased risk for iHF (hazard ratio [HR], 95% confidence interval [CI], 1.30, 1.24–1.36), hHF (HR 1.54, 95% CI 1.44–1.66), all-cause mortality (HR 1.62, 95% CI 1.54–1.70), and CV mortality (HR 1.41 95% CI 1.22–1.63) in the general population and hHF (HR 1.26, 95% CI 1.21–1.54) and all-cause mortality (HR 1.54 95% CI 1.24–1.92) in the HF patient group compared with an FLI < 20. Among participants with NAFLD, advanced liver fibrosis was associated with increased risk for iHF, hHF, and all-cause mortality in the general population and all-cause mortality and CV mortality in the HF patient group (all p < 0.05). CONCLUSION: Hepatic steatosis and/or advanced fibrosis as assessed by FLI and BARD score was significantly associated with the risk of HF and mortality. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12933-021-01374-8. BioMed Central 2021-09-28 /pmc/articles/PMC8479901/ /pubmed/34583706 http://dx.doi.org/10.1186/s12933-021-01374-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Original Investigation
Park, Jiyun
Kim, Gyuri
Kim, Hasung
Lee, Jungkuk
Lee, You-Bin
Jin, Sang-Man
Hur, Kyu Yeon
Kim, Jae Hyeon
The association of hepatic steatosis and fibrosis with heart failure and mortality
title The association of hepatic steatosis and fibrosis with heart failure and mortality
title_full The association of hepatic steatosis and fibrosis with heart failure and mortality
title_fullStr The association of hepatic steatosis and fibrosis with heart failure and mortality
title_full_unstemmed The association of hepatic steatosis and fibrosis with heart failure and mortality
title_short The association of hepatic steatosis and fibrosis with heart failure and mortality
title_sort association of hepatic steatosis and fibrosis with heart failure and mortality
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479901/
https://www.ncbi.nlm.nih.gov/pubmed/34583706
http://dx.doi.org/10.1186/s12933-021-01374-8
work_keys_str_mv AT parkjiyun theassociationofhepaticsteatosisandfibrosiswithheartfailureandmortality
AT kimgyuri theassociationofhepaticsteatosisandfibrosiswithheartfailureandmortality
AT kimhasung theassociationofhepaticsteatosisandfibrosiswithheartfailureandmortality
AT leejungkuk theassociationofhepaticsteatosisandfibrosiswithheartfailureandmortality
AT leeyoubin theassociationofhepaticsteatosisandfibrosiswithheartfailureandmortality
AT jinsangman theassociationofhepaticsteatosisandfibrosiswithheartfailureandmortality
AT hurkyuyeon theassociationofhepaticsteatosisandfibrosiswithheartfailureandmortality
AT kimjaehyeon theassociationofhepaticsteatosisandfibrosiswithheartfailureandmortality
AT parkjiyun associationofhepaticsteatosisandfibrosiswithheartfailureandmortality
AT kimgyuri associationofhepaticsteatosisandfibrosiswithheartfailureandmortality
AT kimhasung associationofhepaticsteatosisandfibrosiswithheartfailureandmortality
AT leejungkuk associationofhepaticsteatosisandfibrosiswithheartfailureandmortality
AT leeyoubin associationofhepaticsteatosisandfibrosiswithheartfailureandmortality
AT jinsangman associationofhepaticsteatosisandfibrosiswithheartfailureandmortality
AT hurkyuyeon associationofhepaticsteatosisandfibrosiswithheartfailureandmortality
AT kimjaehyeon associationofhepaticsteatosisandfibrosiswithheartfailureandmortality